Tuilleadh fiosrachaidh ― Scots gaelic

Is e Squamous cell carcinoma (SCC) an dàrna aillse craiceann as cumanta anns na Stàitean Aonaichte, às deidh basal cell carcinoma. Mar as trice bidh e a’ tòiseachadh le leòintean ro-aillse ris an canar actinic keratosis , agus faodaidh iad sgaoileadh gu pàirtean eile den bhodhaig. Is e am prìomh adhbhar a bhith fosgailte do rèididheachd ultraviolet (UV) bhon ghrèin, a bhios a’ cruinneachadh thar ùine. Mar as trice bidh làimhseachadh a’ toirt a-steach toirt air falbh lannsa, gu sònraichte airson SCC air a’ cheann agus amhach. Tha leigheas rèididheachd na roghainn dha euslaintich nas sine no dhaibhsan aig nach urrainn lannsaireachd fhaighinn. Bidh dìonachd a’ meudachadh cunnart SCC. Ged a tha e tearc, faodaidh SCC sgaoileadh, gu sònraichte ann an euslaintich le siostaman dìon lag. Tha sgrùdaidhean cunbhalach agus dìon grèine cudromach dhaibhsan aig a bheil SCC.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.

Is e Cutaneous squamous cell carcinoma (CSCC) an dàrna aillse as cumanta ann an daoine, agus tha na h-àireamhan aige a’ dol suas. Ged a bhios CSCC mar as trice a’ nochdadh giùlan clionaigeach mì-rianail, faodaidh e sgaoileadh gu h-ionadail agus gu pàirtean eile den bhodhaig. Tha luchd-saidheans air slighean sònraichte a chomharrachadh a tha an sàs ann an leasachadh CSCC, a’ leantainn gu leigheasan ùra. Tha an àireamh àrd de mhùthaidhean agus cunnart nas motha ann an euslaintich le dìon-dìon air brosnachadh leasachadh immunotherapy. Bidh an lèirmheas seo a’ coimhead air freumhan ginteil CSCC agus na leigheasan as ùire a tha ag amas air moileciuilean sònraichte agus an siostam dìon.
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors